Abstract:BackgroundIntracellular accumulation of insoluble tau is an important hallmark of Alzheimer's disease (AD) and related tauopathies. We have previously identified in human tauopathy brain a truncated tau species (Tau35), comprising the C-terminal half with four microtubule-binding repeats. Minimal Tau35 expression in transgenic mice results in a progressive tauopathy phenotype including tau phosphorylation and aggregation, cognitive and behavioural abnormalities and impaired protein clearance. The autophagy-lysosomal pathway (ALP) plays a crucial role in the clearance of protein aggregates and defects in ALP are associated with the pathogenesis of AD. We sought to explore the effect of Tau35 expression on the ALP and whether autophagy is disrupted due to lysosomal dysfunction. MethodsChinese hamster ovary (CHO) cells stably expressing Tau35 (CHO-Tau35) or full-length human 2N4R tau (CHO-FL) were generated. Primary cortical neurons from Tau35 transgenic and wild-type mice were cultured for 14 days in vitro(DIV) and brain homogenates were prepared from mice aged 4 and 12 months. The effect of Tau35 on the ALP was examined using immunofluorescence and western blots. ResultNuclear translocation of transcription factor EB (TFEB), a key mediator of lysosomal biogenesis, was significantly reduced in both CHO-FL and CHO-Tau35 cells. However, only CHO-Tau35 cells exhibited disrupted mammalian target of rapamycin complex 1 (mTORC1) activity and autophagic flux. Expression of ALP markers, including LC3-I/II, LAMP1, LAMP2 and cathepsin D, were also reduced in CHO-Tau35 cells and in post-symptomatic Tau35 transgenic mice. ConclusionsOur findings suggest that N-terminally cleaved tau damages both lysosomal clearance of cellular proteins and lysosomal biogenesis. The Tau35-expressing cultured neurons will provide a useful tool to explore molecular mechanisms underlying tau-induced lysosomal dysfunction, which may lead to the identification of novel therapeutic targets for dementia.

Heterologous expression and fibrillary characterization of the microtubule-binding domain of tau associated with tauopathies

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Tau in neurodegenerative disease

Study on interaction between microtubule associated protein tau and prion protein

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Synthesis and conformational properties of phosphopeptides related to the human tau protein.

Tau in Health and Neurodegenerative Diseases

Probing Conformational Dynamics of Tau Protein by Hydrogen/Deuterium Exchange Mass Spectrometry

Mechanistic Insights and Future Challenges

Structural mapping techniques distinguish the surfaces of fibrillar 1N3R and 1N4R human tau

Tau Ubiquitination in Alzheimer's Disease

The Self-Assembly Ability of the First Microtubule-Binding Repeat from Tau and Its Modulation by Phosphorylation

Tau filaments with the Alzheimer fold in cases with mutations V337M and R406W

Subtle change of fibrillation condition leads to substantial alteration of recombinant Tau fibril structure

Live-cell visualization of tau aggregation in human neurons

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Methods for high throughput discovery of fluoroprobes that recognize tau fibril polymorphs

Molecular Polymorphism of tau aggregates in Pick's disease

Biochemical approaches to assess the impact of post-translational modifications on pathogenic tau conformations using recombinant protein

Polymerization of recombinant tau core fragments in vitro and seeding studies in cultured cells

Advances in Tau-mediated neurodegeneration and Tau-focused drug for Alzhehimer's disease